<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00100854</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000407580</org_study_id>
    <secondary_id>P50CA090388</secondary_id>
    <secondary_id>P30CA016042</secondary_id>
    <secondary_id>UCLA-0407058-01</secondary_id>
    <nct_id>NCT00100854</nct_id>
  </id_info>
  <brief_title>Erlotinib With or Without Fulvestrant in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer</brief_title>
  <official_title>A Randomized, Open-Label Phase II Clinical Trial of Combination Erlotinib (Tarceva®) and Fulvestrant (Faslodex®) Versus Erlotinib (Tarceva®) Alone in Advanced Non-Small Cell Lung Cancer Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Translational Oncology Research International</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Translational Oncology Research International</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Erlotinib may stop the growth of tumor cells by blocking some of the enzymes&#xD;
      needed for cell growth. Estrogen can cause the growth of non-small cell lung cancer cells.&#xD;
      Hormone therapy using fulvestrant may fight non-small cell lung cancer by lowering the amount&#xD;
      of estrogen the body makes. Giving erlotinib together with fulvestrant may kill more tumor&#xD;
      cells. It is not yet known whether giving erlotinib together with fulvestrant is more&#xD;
      effective than erlotinib alone in treating non-small cell lung cancer.&#xD;
&#xD;
      PURPOSE: This randomized phase II trial is studying giving erlotinib together with&#xD;
      fulvestrant to see how well it works compared to erlotinib alone in treating patients with&#xD;
      stage IIIB or stage IV non-small cell lung cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
      Primary&#xD;
&#xD;
        -  Compare objective tumor response in patients stage IIIB or IV non-small cell lung cancer&#xD;
           treated with erlotinib hydrochloride with vs without fulvestrant.&#xD;
&#xD;
      Secondary&#xD;
&#xD;
        -  Correlate response rate with ER and EGF receptor expression in patients treated with&#xD;
           these regimens.&#xD;
&#xD;
        -  Correlate measurement of ER-α, ER-β, EGF/HER-1 receptor and HER-2/neu receptor with&#xD;
           clinical response in patients treated with these regimens.&#xD;
&#xD;
        -  Correlate erlotinib hydrochloride resistance with ER and HER receptor expression in&#xD;
           patients treated with these regimens.&#xD;
&#xD;
      OUTLINE: This is a randomized, open-label, multicenter study. Patients are stratified&#xD;
      according to performance status, gender, and participating center. Patients are randomized to&#xD;
      1 of 2 treatment arms.&#xD;
&#xD;
        -  Arm I: Patients receive oral erlotinib hydrochloride once daily on days 1-28. Courses&#xD;
           repeat every 28 days.&#xD;
&#xD;
        -  Arm II: Patients receive erlotinib hydrochloride as in arm I and fulvestrant&#xD;
           intramuscularly on days 1, 15, and 29, and then every 28 days thereafter.&#xD;
&#xD;
      In both arms, treatment continues in the absence of disease progression or unacceptable&#xD;
      toxicity.&#xD;
&#xD;
      After completion of study treatment, patients are followed for 30 days and then every 2&#xD;
      months until disease progression.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 102 patients (34 in arm I and 68 in arm II) will be accrued for&#xD;
      this study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">October 28, 2004</start_date>
  <completion_date type="Actual">September 5, 2018</completion_date>
  <primary_completion_date type="Actual">September 5, 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Objective tumor response</measure>
    <time_frame>30 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Correlation of response rate with receptor expression</measure>
    <time_frame>30 days</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">108</enrollment>
  <condition>Lung Cancer</condition>
  <arm_group>
    <arm_group_label>Arm I</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients receive oral erlotinib hydrochloride once daily on days 1-28. Courses repeat every 28 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm II</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive erlotinib hydrochloride as in arm I and fulvestrant intramuscularly on days 1, 15, and 29, and then every 28 days thereafter.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>erlotinib hydrochloride</intervention_name>
    <description>Given orally</description>
    <arm_group_label>Arm I</arm_group_label>
    <arm_group_label>Arm II</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>fulvestrant</intervention_name>
    <description>Given intramuscularly</description>
    <arm_group_label>Arm II</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:&#xD;
&#xD;
          -  adults over the age of 18 capable of giving informed consent.&#xD;
&#xD;
          -  Histologically confirmed non-small cell lung cancer&#xD;
&#xD;
          -  Stage IIIB or IV NSCLC&#xD;
&#xD;
          -  Tumor tissue block available.&#xD;
&#xD;
          -  ECOG performance status of 0, 1 or 2.&#xD;
&#xD;
          -  Measurable disease by RECIST criteria defined as ≥ 1 target lesion that has not been&#xD;
             irradiated. New lesions that have developed in a previously irradiated field may be&#xD;
             used as sites of measurable disease provided all other criteria are met.&#xD;
&#xD;
          -  Meets 1 of the following criteria:&#xD;
&#xD;
          -  Progressive disease after ≥ 1 prior standard chemotherapy regimen&#xD;
&#xD;
          -  Refused chemotherapy&#xD;
&#xD;
          -  Unable to receive standard chemotherapy&#xD;
&#xD;
          -  women of childbearing age must have negative pregnancy test by urine or serum prior to&#xD;
             initiation of treatment. men and women of childbearing potential must consent to using&#xD;
             adequate contraception throughout treatment and for 3 months following surgery.&#xD;
&#xD;
        Exclusion criteria:&#xD;
&#xD;
          -  Renal insufficiency (serum creatinine &gt;2mg/dl)&#xD;
&#xD;
          -  Liver insufficiency (serum total bilirubin &gt;1.5X ULN, or serum transaminases &gt; 2.5X&#xD;
             the ULN or %X ULN if hepatic metastases).&#xD;
&#xD;
          -  hematologic abnormality platelets&lt; 100,000 ANC &lt;1,500/mm3&#xD;
&#xD;
          -  THerapeutic anticoagulation will be allowed, but patients receiving fulvestrant while&#xD;
             on therapeutic anticoagulation will have the fulvestrant dose divided into twice as&#xD;
             many syringes to minimize the volume of intramuscular injection in these patients. In&#xD;
             patients receiving low molecular weight heparin or fondaparinux, these medications&#xD;
             should be held for 12 hours before and after fulvestrant injection if possible.&#xD;
&#xD;
          -  Active CNS metastases.&#xD;
&#xD;
          -  New York Heart Association class III or IV cardiac disease&#xD;
&#xD;
          -  myocardial infarction within the past 12 months&#xD;
&#xD;
          -  symptomatic ventricular arrhythmia&#xD;
&#xD;
          -  symptomatic conduction abnormality&#xD;
&#xD;
          -  evidence of clinically active interstitial lung disease&#xD;
&#xD;
          -  Patients with asymptomatic chronic stable radiographic changes are eligible&#xD;
&#xD;
          -  pregnant or nursing or inadequate contraception&#xD;
&#xD;
          -  hypersensitivity to erlotinib hydrochloride or fulvestrant or to any of their&#xD;
             excipients&#xD;
&#xD;
          -  comorbid disease or medical condition that would preclude study treatment or&#xD;
             compliance&#xD;
&#xD;
          -  malignancy within the past 3 years except nonmelanoma skin cancer or carcinoma in situ&#xD;
             of the cervix&#xD;
&#xD;
          -  chemotherapy or non-cytotoxic investigational agents within 4 weeks of initiating&#xD;
             treatment.&#xD;
&#xD;
          -  major surgery within 4 weeks of initiating therapy. Minor surgery within 7 days of&#xD;
             initiating therapy.&#xD;
&#xD;
          -  anticancer antiestrogen therapy. Concurrent stable-dose steroids allowed&#xD;
&#xD;
          -  concomitant radiation therapy to the lungs. Radiation therapy to non-target lesions&#xD;
             will be allowed as long as it is completed 1 week prior to initiation of treatment.&#xD;
&#xD;
          -  prior anticancer epidermal growth factor receptor inhibitors&#xD;
&#xD;
          -  concurrent CYP3A4 inducers, including any of the following:&#xD;
&#xD;
          -  Phenytoin&#xD;
&#xD;
          -  Carbamazepine&#xD;
&#xD;
          -  Rifampin&#xD;
&#xD;
          -  Barbiturates&#xD;
&#xD;
          -  Hypericum perforatum (St. John's wort)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Edward Garon, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Jonsson Comprehensive Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Jonsson Comprehensive Cancer Center at UCLA</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095-1781</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2019</verification_date>
  <study_first_submitted>January 6, 2005</study_first_submitted>
  <study_first_submitted_qc>January 6, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 7, 2005</study_first_posted>
  <last_update_submitted>March 1, 2019</last_update_submitted>
  <last_update_submitted_qc>March 1, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">March 5, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>stage IIIB non-small cell lung cancer</keyword>
  <keyword>stage IV non-small cell lung cancer</keyword>
  <keyword>recurrent non-small cell lung cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Erlotinib Hydrochloride</mesh_term>
    <mesh_term>Fulvestrant</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

